Chuang Hao-Yuan (Chief Financial Officer) sold $3.5M of stock, under a pre-arranged trading plan
SEC Form 4
Belite BIO, Inc is a US-listed company in the biotechnology industry. Its financial year ends in December.
Stock price today
Loading chart…
Third-party market data · may be delayed
Fair value per share
Under review: every model's value for Belite BIO, Inc is far from the share price, which usually points to a data problem (a merger, a share-count change, a one-off) rather than a bargain or a bubble.
Price vs value
Under review: limited reported history: available models are shown without a Buy/Hold/Sell rating. We'll show the comparison once resolved.
Belite BIO, Inc valuation: adjust assumptions and compare models →
Who’s trading
What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.
- Insiders0 buying, 5 selling0 purchases and 175 sales by directors and officers, last 12 monthsInsider trades
- Funds50 adding, 37 cuttingOf 28 active managers that changed their stake, 16 added; quarter to June 30, 2026Fund buyers and sellers
The Fundamentalytics view
Current signal Free cash flow diverging from earnings: TTM free cash flow fell 26.3% while net income fell 114.7%: a 88pp divergence.
Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.
Highlights
How we pick theseStrengths
- Estimates rising. Analysts' consensus for next year's earnings per share has risen 138.6% over 90 days.
Things to watch
- Share dilution. Diluted shares rose 9.8% in a year.
- Insiders selling. 5 insiders sold $41M of stock over the past 365 days and none bought (93% under pre-set trading plans).
- Short interest rising. Shares sold short rose 21% in a month to 6.0% of tradable shares.
- Missing expectations. Earnings per share fell short of the consensus estimate in 3 of the last four quarters.
Latest results
- Earnings per share
- -$0.70 against an average estimate of -$0.78: beat by 9.9%
- Next report
- November 9, 2026; average EPS estimate -$0.77
Price chart
- 1 day-0.7%
- 1 week+7.2%
Loading chart…
Third-party market data · may be delayed
At a glance
Profitability
- EPS (TTM, diluted)
- $-2.31
Growth
- Share count change
- +9.8%
Cash
- Free cash flow (TTM)
- -$37.1M
News & updates
Company announcements, filed results and changes that matter to shareholders.
- Insider trade
- Insider trade
Lin Yu-Hsin (Chief Executive Officer) sold $5.1M of stock, under a pre-arranged trading plan
SEC Form 4 - Insider trade
Chuang Hao-Yuan (Chief Financial Officer) sold $1.3M of stock, under a pre-arranged trading plan
SEC Form 4
The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.
Valuation models
We value Belite BIO, Inc as an operating company, with every model that fits that kind of business. Cost of equity 9.9%: the 10-year Treasury yield (4.9%) plus a beta of 1.1 times a 4.5% equity risk premium.
| Model | Value per share | In the combined value? |
|---|---|---|
| Forward price-to-earnings vs peers Next year's consensus earnings per share times peers' typical (harmonic-mean) forward price-to-earnings. Uses analysts' consensus estimates (third-party data), not our forecasts. | ~$28 ~$26–$53 | Left out: out of range vs price (0.18x) |
| Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. | ~$21 ~$22–$82 | Left out: out of range vs price (0.14x) |
| Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. | — | Combined value withheld. Review the individual models and their assumptions. |
Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Belite BIO, Inc with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.
Moat
Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.
Forecasts and guidance
Next results: November 9, 2026, after the close. Analysts expect revenue of $0 and EPS of −$0.77 (range −$1.16 to −$0.52) for the quarter.
Analysts' consensus
| Fiscal year | EPS | Growth | Revenue | Growth |
|---|---|---|---|---|
| Current | −$2.94 | −27% | — | 0% |
| Next | $2.26 | +177% | $274m | 0% |
Next year's EPS estimate has moved +138.6% in 90 days, across 8 analysts.
How the EPS forecast has moved
The consensus EPS forecast for the current fiscal year is −11.0% on 90 days ago. In the last 30 days, 3 analysts raised Belite BIO, Inc's forecast and 1 cut it.
Average of analysts' published estimates (third-party data).
View chart data
| Period | Current fiscal year | Next fiscal year |
|---|---|---|
| 90 days ago | −$3.30 | $0.95 |
| 60 days ago | −$2.95 | $2.14 |
| 30 days ago | −$2.94 | $2.26 |
| 7 days ago | −$2.94 | $2.26 |
| Now | −$2.94 | $2.26 |
Earnings against estimates
| Quarter to | Estimate | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | −$0.78 | −$0.70 | +9.9% |
| Mar 2026 | −$0.64 | −$0.68 | −5.8% |
| Dec 2025 | −$0.54 | −$0.70 | −30.3% |
| Sept 2025 | −$0.49 | −$0.65 | −32.7% |
Adjusted EPS as companies report it, against the average analyst estimate.
Positioning
- Short interest
- 6.0% of tradable shares
- Days to cover
- 7.77 at average volume
- Short interest, 1 month
- +21% to October 15, 2026
- Held by institutions
- 24% of shares
- Held by insiders
- 43.7% of shares
- Employees
- 41 full time
Share-price performance
Market data may be delayedPrice behaviour
- 52-week range
- Not enough history
- From 52-week high
- —
- vs 50-day average
- —
- vs 200-day average
- —
- Volatility (1 year)
- —
- Beta vs S&P 500
- —
Fundamentals
Financial health
- Short-term assets cover short-term liabilities $494m of assets due within a year against $10m of liabilities due within a year.
- Short-term assets cover long-term liabilities $494m short-term assets against $188,000 of longer-dated liabilities.
- More cash than debt Cash or debt not separately reported. Not assessable.
- Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
- Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
- A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
- Operating profit covers interest at least five times over Operating income of −$84m against $2,000 of interest.
Dividends, buybacks and capital spending
- Diluted share count
- +9.8%
- year over year
Who owns it
Funds buying and selling- Reported value
- $1.4B
- Institutions reporting
- 81
- Shares held vs prior quarter
- ▲ 3.9%
- Positions opened / closed
- 22 / 15
| Manager | Value | Shares | Share of 13F value | Shares QoQ |
|---|---|---|---|---|
| Darwin Global Management, Ltd. | $457M | 3.1M | 31.7% | ▲ 0.6% |
| Paradigm Biocapital Advisors LP | $190M | 1.2M | 13.2% | ▲ 10.6% |
| RTW Investments, LP | $110M | 715K | 7.6% | 0.0% |
| Millennium Management LLC | $76.2M | 495K | 5.3% | ▼ 13.2% |
| Maverick Capital Ltd | $61M | 396K | 4.2% | New |
| Eventide Asset Management, LLC | $60.2M | 391K | 4.2% | ▲ 9.3% |
| Deerfield Management Company, L.P. | $55M | 357K | 3.8% | ▲ 17.5% |
| Holocene Advisors, LP | $38.7M | 251K | 2.7% | ▼ 49.2% |
| Logos Global Management LP | $38.5M | 250K | 2.7% | New |
| Morgan Stanley | $36.2M | 235K | 2.5% | ▲ 16.7% |
| UBS Group AG | $34.6M | 225K | 2.4% | ▼ 70.7% |
| Citadel Advisors LLC | $28.7M | 186K | 2.0% | ▲ 9171.3% |
From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Belite BIO, Inc's complete shareholder register. Values are as reported by the filers .
Insider trading activity
Full insider history and chart Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $40.6M 175 trades by 5 insiders · 93% under pre-set plans
Net ▼ $40.6M net selling
| Insider | Date | Trade | Shares | Price | Value |
|---|---|---|---|---|---|
| Scholl Hendrik Peter Chief Medical Officer | October 1, 2026 | Sell pre-set plan | 2 | $170.02 | $340 |
| Scholl Hendrik Peter Chief Medical Officer | October 1, 2026 | Sell pre-set plan | 14 | $169.36 | $2,371 |
| Scholl Hendrik Peter Chief Medical Officer | October 1, 2026 | Sell pre-set plan | 12 | $168.21 | $2,019 |
| Scholl Hendrik Peter Chief Medical Officer | October 1, 2026 | Sell pre-set plan | 78 | $167.59 | $13,072 |
| Scholl Hendrik Peter Chief Medical Officer | October 1, 2026 | Sell pre-set plan | 50 | $166.44 | $8,322 |
| Scholl Hendrik Peter Chief Medical Officer | October 1, 2026 | Sell pre-set plan | 120 | $165.49 | $19,859 |
| Scholl Hendrik Peter Chief Medical Officer | October 1, 2026 | Sell pre-set plan | 24 | $164.64 | $3,951 |
| Scholl Hendrik Peter Chief Medical Officer | October 1, 2026 | Sell pre-set plan | 200 | $163.63 | $32,725 |
| Chuang Hao-Yuan Chief Financial Officer | September 8, 2026 | Sell pre-set plan | 4,605 | $197.23 | $908,244 |
| Chuang Hao-Yuan Chief Financial Officer | September 8, 2026 | Sell pre-set plan | 4,475 | $196.47 | $879,203 |
| Chuang Hao-Yuan Chief Financial Officer | September 8, 2026 | Sell pre-set plan | 4,120 | $195.60 | $805,872 |
| Chuang Hao-Yuan Chief Financial Officer | September 8, 2026 | Sell pre-set plan | 2,200 | $194.28 | $427,416 |
From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.
Earnings dates and SEC filings
Data status
| Data | Last updated | Source |
|---|---|---|
| Share price | Exchange closing prices | |
| News and updates | Company releases and SEC 8-K filings | |
| Analyst estimates | Aggregated analyst estimates | |
| Valuation and scores | Our models, from the filed figures |
Belite BIO, Inc in brief
- What does Belite BIO, Inc do?
- Belite BIO, Inc is a US-listed company in the biotechnology industry. Its financial year ends in December.
- What is Belite BIO, Inc's stock ticker?
- Belite BIO, Inc trades under the ticker BLTE on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
- Who are Belite BIO, Inc's largest institutional shareholders?
- By value reported in 13F filings for June 30, 2026, the largest reported holders are Darwin Global Management, Ltd., Paradigm Biocapital Advisors LP and RTW Investments, LP. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
- Are insiders buying or selling Belite BIO, Inc stock?
- Over the last 12 months, Belite BIO, Inc's directors and officers reported 0 open-market purchases and 175 sales on Form 4. The insider trading page charts every trade.
- When is Belite BIO, Inc's next earnings date?
- Around November 9, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Belite BIO, Inc announces its own schedule.
Follow research on Belite BIO, Inc
New research on the companies we cover arrives in the weekly email. Free, one email a week.